

SURMODICS INC  
Form 4  
August 18, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**OLSON CHARLES W**

(Last) (First) (Middle)

9924 WEST 74TH STREET

(Street)

EDEN PRAIRIE, MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**SURMODICS INC [SRDX]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**08/16/2016**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**Senior VP & GM, Med Dev**

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |            |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|------------|
|                                 |                                      |  |                                | Code  | V   | Amount   | (A) or (D)  | Price      |
| Common Stock                    | 08/16/2016                           |  | S                              |   | 4,383   | D  |   | \$ 29.1759 |
|                                 |                                      |  |                                |   |   |  |   | 33,098 (1) |
| Common Stock                    | 08/16/2016                           |  | S                              |   | 1,528   | D  |   | \$ 29.0195 |
|                                 |                                      |  |                                |   |   |  |   | 31,570 (2) |
| Common Stock                    | 08/17/2016                           |  | S                              |   | 1,000   | D  |   | \$ 29      |
|                                 |                                      |  |                                |   |   |  |   | 30,570     |
| Common Stock                    | 08/17/2016                           |  | S                              |   | 2,000   | D  |   | \$ 28.6485 |
|                                 |                                      |  |                                |   |   |  |   | 28,570 (3) |



## Edgar Filing: SURMODICS INC - Form 4

upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(2) Reflects the weighted average price of 1,528 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on August 16, 2016 with sale prices ranging from \$29.00 to \$29.043 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(3) Reflects the weighted average price of 2,000 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on August 17, 2016 with sale prices ranging from \$28.55 to \$29.02 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(4) Reflects the weighted average price of 1,025 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on August 17, 2016 with sale prices ranging from \$28.51 to \$28.75 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.